2021-2022 has not been kind to this dark knight of the cannabis industry.
Hexo was one of my biggest conviction cannabis stocks last year.
When Hexo bought Redecan at a valuation of nearly a billion dollars last year I thought it would turn around.
But I learnt it was just chopping off an arm and leg as interest rates went up and valuations went down.
Nearly a year later and a reverse stock split a few days ago, Hexo is looking to call it a draw.
Hexo was one of my biggest conviction cannabis stocks last year.
When Hexo bought Redecan at a valuation of nearly a billion dollars last year I thought it would turn around.
But I learnt it was just chopping off an arm and leg as interest rates went up and valuations went down.
Nearly a year later and a reverse stock split a few days ago, Hexo is looking to call it a draw.
Commentaire:
No cannabis bill in US next year would likely see HEXO delisted.
Tilray would do well buying Hexo at this discount.
The research into Grow Ops, Terpenes, CBD, preroll and strains created by Redecan could be acquired at pennies to the dollar.